Page 119 - 《中国药房》2025年22期

参考文献 comes with once-weekly insulin icodec versus once-daily
[ 1 ] ZHOU Y C，LIU J M，ZHAO Z P，et al. The national and insulin glargine U100 in insulin-naïve and previously
provincial prevalence and non-fatal burdens of diabetes in insulin-treated individuals with type 2 diabetes：a meta-
China from 2005 to 2023 with projections of prevalence analysis of randomised controlled trials[J]. Endocrinol
to 2050[J]. Mil Med Res，2025，12（1）：28. Diabetes Metab，2024，7（3）：e00480.
[ 2 ] WILLIAMS R，KARURANGA S，MALANDA B，et al. [14] BAJAJ H S，ÁSBJÖRNSDÓTTIR B，BARI T J，et al.
Global and regional estimates and projections of diabetes- Once-weekly insulin icodec compared with daily basal in‐
related health expenditure：results from the International sulin analogues in type 2 diabetes：participant-level meta-
Diabetes Federation Diabetes Atlas，9th edition[J]. Diabe‐ analysis of the ONWARDS 1-5 trials[J]. Diabetes Obes
tes Res Clin Pract，2020，162：108072. Metab，2024，26（9）：3810-3820.
[ 3 ] ZHONG V W，YU D M，ZHAO L Y，et al. Achievement [15] 崔智程，凤心雨，鲁一兵，等 . 胰岛素 Icodec 治疗 2 型糖
of guideline-recommended targets in diabetes care in 尿病的疗效及安全性的Meta分析[J]. 中华糖尿病杂志，
China：a nationwide cross-sectional study[J]. Ann Intern 2024，16（2）：226-232.
Med，2023，176（8）：1037-1046. [16] MUKHOPADHYAY P，CHATTERJEE P，PANDIT K，et
al. Once-weekly insulin icodec as compared to once-daily
[ 4 ] 中华医学会糖尿病学分会 . 中国糖尿病防治指南：2024
basal insulins：a meta-analysis[J]. Endocr Pract，2024，30
版[J]. 中华糖尿病杂志，2025，17（1）：16-139.
（2）：128-134.
[ 5 ] KJELDSEN T B，HUBÁLEK F，HJØRRINGGAARD C
U，et al. Molecular engineering of insulin icodec，the first [17] SALEEM S Z，FAREED A，AKHTAR S M M，et al. Effi‐
cacy and safety of once-weekly insulin icodec compared
acylated insulin analog for once-weekly administration in
to once-daily insulin g U-100 in patients with type Ⅱ dia‐
humans[J]. J Med Chem，2021，64（13）：8942-8950.
betes：a systematic review and meta-analysis[J]. Diabetol
[ 6 ] NISHIMURA E，PRIDAL L，GLENDORF T，et al.
Metab Syndr，2024，16（1）：80.
Molecular and pharmacological characterization of insulin
[18] SHETTY S，SUVARNA R. Efficacy and safety of once-
icodec：a new basal insulin analog designed for once-
weekly insulin icodec in type 2 diabetes：a meta-analysis
weekly dosing[J]. BMJ Open Diabetes Res Care，2021，9
of ONWARDS phase 3 randomized controlled trials[J].
（1）：e002301.
Diabetes Obes Metab，2024，26（3）：1069-1081.
[ 7 ] 唐惠林，门鹏，翟所迪. 药物快速卫生技术评估方法及应
[19] ZUHAIR V，OBAID M A，MUSTAFA M S，et al. Evalua-
用[J]. 临床药物治疗杂志，2016，14（2）：1-4.
ting the efficacy and safety of weekly insulin icodec vs.
[ 8 ] 张方圆，沈傲梅，曾宪涛，等. 系统评价方法学质量评价
daily insulin glargine in type 2 diabetes mellitus：a syste-
工具 AMSTAR 2 解读[J]. 中国循证心血管医学杂志，
matic review and meta-analysis[J]. J Diabetes Metab
2018，10（1）：14-18.
Disord，2024，23（1）：1337-1349.
[ 9 ] HUSEREAU D，DRUMMOND M，AUGUSTOVSKI F，
[20] DAI N，SU X R，WANG Y. Cost-utility analysis of once-
et al. Consolidated health economic evaluation reporting
weekly insulin icodec and once-daily insulin glargine in
standards 2022 （CHEERS 2022） statement：updated patients with type 2 diabetes receiving basal-bolus insulin
reporting guidance for health economic evaluations[J].
therapy in China[J]. Diabetes Obes Metab，2025，27（1）：
Value Health，2022，25（1）：3-9.
377-386.
[10] DUTTA D，NAGENDRA L，BHAT S，et al. Optimal use
[21] HU S S，WANG S W，GU S Y，et al. Cost-utility analysis
of once weekly icodec insulin in type-2 diabetes：an up‐
and drug pricing of once-weekly insulin icodec versus
dated meta-analysis of phase-2 and phase-3 randomized once-daily insulin degludec for type 2 diabetes patients
controlled trials[J]. Diabetes Metab Syndr，2023，17（10）： treated with basal insulin in China[J]. Diabetes Obes
102877. Metab，2024，26（12）：5995-6006.
[11] RIBEIRO E SILVA R，DE MIRANDA GAUZA M， [22] TORRE E，DI MATTEO S，BRUNO G M，et al. Eco‐
GUISSO M E S，et al. Once-weekly insulin icodec vs. nomic evaluation of once-weekly insulin icodec from Italian
once-daily insulin glargine U100 for type 2 diabetes：a sys‐ NHS perspective[J]. Clinicoecon Outcomes Res，2024，
tematic review and meta-analysis of phase 2 randomized 16：799-811.
controlled trials[J]. Arch Endocrinol Metab，2023，67（5）： [23] BAJAJ H S，ABERLE J，DAVIES M，et al. Once-weekly
e000614. insulin icodec with dosing guide app versus once-daily
[12] ABUELAZM M，IBRAHIM A A，KHLIDJ Y，et al. Once- basal insulin analogues in insulin-naive type 2 diabetes
weekly insulin icodec versus once-daily long-acting insu‐ （ONWARDS 5）：a randomized trial[J]. Ann Intern Med，
lin for type Ⅱ diabetes：a meta-analysis of randomized 2023，176（11）：1476-1485.
controlled trials[J]. J Endocr Soc，2023，8（2）：bvad177. （收稿日期：2025-08-04 修回日期：2025-10-31）
[13] AHMED M，SHAFIQ A，JAVAID H，et al. Clinical out‐ （编辑：孙 冰）

中国药房 2025年第36卷第22期 China Pharmacy 2025 Vol. 36 No. 22 · 2861 ·